Nafamostat

Base Information

• Chemical Name: Nafamostat
• CAS No.: 81525-10-2
• Molecular Formula: C19H17N5O2
• Molecular Weight: 347.376
• UNII: Y25LQ0H97D
• DSSTox Substance ID: DTXSID0048420
• Nikkaji Number: J33.163E
• Wikipedia: Nafamostat
• Wikidata: Q15409374
• NCI Thesaurus Code: C96292
• Pharos Ligand ID: TS79G7GAB2QX
• Metabolomics Workbench ID: 153559
• ChEMBL ID: CHEMBL273264
• Mol file: 81525-10-2.mol

Synonyms:6'-amidino-2-naphthyl 4-guanidinobenzoate;6'-amidino-2-naphthyl 4-guanidinobenzoate, dimethanesulfonate;Benzoic acid, 4-((aminoiminomethyl)amino)-, 6-(aminoiminomethyl)-2-naphthalenyl ester;Benzoic acid, 4-((aminoiminomethyl)amino)-, 6-(aminoiminomethyl)-2-naphthalenyl ester, dihydrochloride;Benzoic acid, 4-((aminoiminomethyl)amino)-, 6-(aminoiminomethyl)-2-naphthalenyl ester, dimethanesulfonate;CKD-314;CKD314;FUT 175;FUT-175;nafamostat;nafamostat dihydrochloride;nafamostat mesilate;nafamostat mesylate;nafamstat mesilate;Ronastat

Chemical Property of Nafamostat

Chemical Property:

• Vapor Pressure: 3.9E-16mmHg at 25°C
• Refractive Index: 1.694
• Boiling Point: 637.2 °C at 760 mmHg
• PKA: 11.30±0.30(Predicted)
• Flash Point: 339.1 °C
• PSA: 138.07000
• Density: 1.39 g/cm³
• LogP: 4.32150
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• XLogP3: 2
• Hydrogen Bond Donor Count: 4
• Hydrogen Bond Acceptor Count: 4
• Rotatable Bond Count: 5
• Exact Mass: 347.13822480
• Heavy Atom Count: 26
• Complexity: 552

Purity/Quality:

Nafamostat ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N
• Recent ClinicalTrials: Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314
• Recent EU Clinical Trials: A Randomized Clinical Trial of Nafamostat: A Potent Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor for the Treatment of Covid-19
• Recent NIPH Clinical Trials: Continuous regional arterial infusion (CRAI) versus venous infusion of Nafamostat mesilate for severe acute pancreatitis: a multicenter, open-label, randomized controlled trial.